llms-full.txt · Vyos Life

# Vyos Life · llms-full.txt This file consolidates the primary editorial content of https://vyoslife.com into a single Markdown document for ingestion by large language models. It complements `llms.txt` (which is the navigational index) by providing full-text content extractable in one fetch. Generated dynamically from the live theme. Last regenerated: 2026-06-05. --- ## About Vyos Life Vyos Life is a clinical-grade precision nutraceutical brand. The brand's working thesis is molecular engineering for human longevity: every product is built around standardized bioactives, peer-reviewed dosing, and independent third-party laboratory verification. The current flagship product is OsteoGuard, a dietary supplement engineered around the BioMatrix formulation: a four-active joint-support protocol comprising: - Boswellia serrata standardized to 65% AKBA (Acetyl-11-keto-beta-boswellic acid). Selectively modulates 5-LOX, the enzyme that produces leukotrienes in joint tissue. Standardization at 65% matches clinical trial dose ranges. - Plant-fermented glucosamine sulfate (GlucosaGreen). Produced by microbial fermentation of corn glucose. Chemically identical to shellfish-derived glucosamine but free of allergens. Provides amino sugar substrates for cartilage matrix synthesis. - Hyaluronic acid at 120 kDa molecular weight. Low-MW fraction documented to absorb orally and reach systemic circulation. Supports synovial fluid viscoelasticity through systemic HA turnover. - Curcumin standardized to 95% curcuminoids with piperine (BioPerine). Piperine inhibits glucuronidation clearance, raising plasma curcumin exposure by approximately 2000% per Shoba 1998 (PMID 9619120). Curcumin attenuates NF-kB-driven inflammatory transcription, including MMP-13 expression. Target audience: US and EU adults seeking evidence-based supplementation. OsteoGuard serves those seeking joint comfort and mobility support; additional flagships are in development in adjacent longevity categories following the same formulation standards. Compliance framework: FDA dietary supplement regulations (US), EFSA food supplement regulations (EU). Structure/function claims only. The brand does not make disease claims. Editorial authorship: content is produced by the in-house Vyos Clinical Desk following the methodology published at https://vyoslife.com/pages/editorial-standards. Claims that require specialized medical judgment beyond our scope cite the authoritative primary source directly (PubMed, NIH, NHS, Mayo Clinic). --- ## Canonical pages - Homepage: https://vyoslife.com/ - OsteoGuard product: https://vyoslife.com/products/osteoguard - Research Journal: https://vyoslife.com/blogs/journal - BioMatrix Science: https://vyoslife.com/pages/science - BioMatrix Ingredients hub: https://vyoslife.com/pages/ingredients - Editorial Standards: https://vyoslife.com/pages/editorial-standards - Joint Health Glossary: https://vyoslife.com/pages/glossary - Certificates of Analysis: https://vyoslife.com/pages/coa - Sitemap: https://vyoslife.com/sitemap.xml --- ## Ingredient reference pages (full content) ### Boswellia serrata (65% AKBA) URL: https://vyoslife.com/pages/boswellia-akba Boswellia serrata is a resin-producing tree whose extract, standardized to 65% AKBA, selectively modulates the 5-LOX inflammatory pathway without the gastric side-effect profile of COX-inhibiting NSAIDs. Mechanism: AKBA selectively binds 5-lipoxygenase (5-LOX), modulating the synthesis of leukotrienes (especially LTB4) without affecting cyclooxygenase (COX). The result is reduction of leukotriene-driven inflammation amplification while preserving prostaglandin homeostasis (gastric mucosa protected, prostacyclin/thromboxane balance preserved). Why 65% AKBA: whole-resin extracts contain 1-7% AKBA. At those concentrations, the active fraction is too dilute to reach plasma levels associated with clinical effect. 65% standardization matches the dose used in published RCTs. Clinical evidence: - Sengupta 2008 (Arthritis Res Ther, PMID 18667054): 75 subjects, 90 days, 5-Loxin standardized AKBA at 100 mg and 250 mg. Statistically significant improvement in VAS pain, WOMAC function, Lequesne. Onset day 7 in higher dose arm. - Kimmatkar 2003 (Phytomedicine, PMID 12622457): 30 subjects, 8 weeks, knee OA. Significant pain reduction, improved knee flexion, increased walking distance. - Vishal 2011 (Int J Med Sci, PMID 22022214): 60 subjects, Aflapin AKBA preparation 100 mg daily. Significant WOMAC improvement at day 5. Dose: 100-250 mg of AKBA per day, split across two doses with food. Lipophilic compound benefits from dietary fat for absorption. Timeline: day 7-14 subjective change; day 30 measurable WOMAC; day 90 plateau. Safety: well tolerated. Mild antiplatelet activity (consult physician if on warfarin or anticoagulants). Discontinue 2 weeks pre-surgery. Insufficient pregnancy data. ### Plant-fermented glucosamine (GlucosaGreen) URL: https://vyoslife.com/pages/plant-glucosamine-glucosagreen Plant-fermented glucosamine sulfate is produced by microbial fermentation of corn glucose by Aspergillus niger, yielding the same molecule as shellfish-derived glucosamine without animal origin or allergen risk. Mechanism: glucosamine is an amino sugar used by chondrocytes to synthesize glycosaminoglycans and proteoglycans, the building blocks of cartilage matrix. Oral supplementation raises the available substrate pool, supporting matrix turnover. Source comparison: - Shellfish-derived: chitin extracted from crustacean exoskeletons, hydrolyzed and deacetylated. Carries shellfish allergen residues, marine source variability, iodine residues. Not vegan. - Plant-fermented (GlucosaGreen): corn glucose fermented by Aspergillus niger, controlled substrate. No allergens, vegan, tighter batch consistency. Clinical evidence: - Reginster 2001 (Lancet, PMID 11214127): 212 subjects, 3 years, 1500 mg glucosamine sulfate daily. Reduced radiographic joint-space narrowing and improved WOMAC vs placebo. - Pavelka 2002 (Arch Intern Med, PMID 12390062): 3-year RCT replicating Reginster finding. - Persiani 2005 (Osteoarthritis Cartilage, PMID 16168682): plasma pharmacokinetics confirming oral absorption. The clinical evidence applies equally to plant-fermented glucosamine because the molecule is identical. Dose: 1500 mg glucosamine sulfate daily (sulfate form, not HCl). Onset 8-12 weeks symptomatic; structural benefit at 3 years. ### Hyaluronic acid (120 kDa) URL: https://vyoslife.com/pages/hyaluronic-acid-joint-support Hyaluronic acid at 120 kDa is a low-molecular-weight fraction documented to absorb through the gut wall, reach systemic circulation, and support synovial fluid viscoelasticity over weeks of consistent use. Why molecular weight matters: HA is a polymer ranging from oligomeric forms (under 20 kDa) to several MDa. Pharmacokinetic studies (Balogh 2008, PMID 19053387) show oral absorption is meaningful only for fractions under approximately 500 kDa. 120 kDa is the midpoint of the absorbable range and the fraction most consistently used in human clinical trials. Mechanism: oral HA enters systemic circulation via gut absorption and lymphatic uptake, contributing to the body's ongoing HA turnover. Distinct from intra-articular HA injections, which place high-MW HA directly into the joint capsule for immediate local viscoelastic effect. Clinical evidence: - Oe 2016 (Nutrition Journal, PMID 26818459): systematic review of oral HA RCTs in knee joint comfort. Aggregate finding supports oral HA at low MW for joint support over 8-12 weeks. - Kalman 2008 (Nutrition Journal, PMID 18416885): natural HA extract in symptomatic knee OA, 8 weeks, measurable VAS improvement. Dose: 80-200 mg per day, low-MW fraction. Onset 8-12 weeks. Label literacy: HA products that do not disclose the kDa fraction are selling a black box. The same milligram weight on the label can deliver meaningfully different systemic HA depending on which fraction is inside the capsule. ### Curcumin + Piperine (95% curcuminoids) URL: https://vyoslife.com/pages/curcumin-piperine-bioavailability Curcumin is the principal polyphenol in turmeric (Curcuma longa). Standardized to 95% curcuminoids with piperine (BioPerine) for bioavailability enhancement, it modulates NF-kB-driven inflammatory transcription. The bioavailability problem: oral curcumin is rapidly conjugated by hepatic and intestinal UDP-glucuronosyltransferase (UGT), producing hydrophilic conjugates excreted before reaching therapeutic plasma levels. Without an enhancer, plasma curcumin reaches only low nanomolar concentrations after multi-gram oral doses (Anand 2007, PMID 17999464). Piperine mechanism: piperine, the alkaloid in black pepper, selectively inhibits UGT enzymes. Co-administration with curcumin extends plasma residence time. Shoba 1998 (Planta Medica, PMID 9619120) documented approximately 2000% higher plasma curcumin exposure when 2 g curcumin was co-administered with 20 mg piperine in human volunteers. Mechanism in joint tissue: curcumin attenuates activation of the NF-kB transcription factor family, reducing downstream expression of inflammatory genes including IL-1, TNF-alpha, COX-2, and MMP-13. Clinical evidence: - Daily 2016 (J Med Food, PMID 27533649): meta-analysis of turmeric extracts and curcumin RCTs in joint arthritis. Aggregated effect size statistically significant for pain and function. - Kuptniratsaikul 2014 (Clin Interv Aging, PMID 24672232): curcumin extract vs ibuprofen in knee OA, 4 weeks. Comparable WOMAC improvement, better GI tolerability for curcumin. Piperine interactions: at supplement doses (5-20 mg), piperine can slow clearance of medications metabolized by UGT and some CYP enzymes (anticoagulants, anticonvulsants, immunosuppressants, some statins). Consult physician if concurrent prescribing. --- ## Editorial standards summary Hierarchy of evidence (from strongest to weakest): 1. Randomized controlled trials (RCTs) indexed in PubMed 2. Systematic reviews and meta-analyses from peer-reviewed journals 3. Guidance from recognized clinical institutions (NIH, NHS, Mayo Clinic, Cleveland Clinic, Harvard Health) 4. Mechanistic studies in indexed biomedical journals Anecdotal sources, unsourced articles, and commercial white papers from competitors are never cited as primary evidence. Claim framework: structure/function claims only ("supports joint comfort", "maintains cartilage matrix"). Disease claims ("cures", "treats", "prevents") are prohibited. Authorship: in-house byline "Vyos Clinical Desk" by default. Articles touching medical conditions are reviewed by independent clinicians when the topic requires it; reviewer name and date appear on the article. Citations: PubMed PMID or DOI inline in body. Replicated in JSON-LD `citation[]` for machine extraction. Corrections: edited inline with `dateModified` and `lastReviewed` updated. Material changes get a dated correction note at the article end. Conflict of interest: Vyos Life sells dietary supplements. Articles may reference Vyos products when directly relevant. No paid placement for third-party products. No sponsored content. --- ## Glossary (short definitions) - 5-Lipoxygenase (5-LOX): enzyme converting arachidonic acid into leukotrienes. AKBA modulation target. - Cyclooxygenase-2 (COX-2): inducible enzyme producing prostaglandins. Main NSAID target. - Matrix metalloproteinase-13 (MMP-13): collagenase that degrades type II collagen, central to cartilage breakdown in osteoarthritis. - AKBA (Acetyl-11-keto-beta-boswellic acid): most active boswellic acid, selective 5-LOX modulator. - Extracellular matrix (ECM): three-dimensional protein-polysaccharide network outside cells. Cartilage ECM is type II collagen + aggrecan + HA. - NF-kB: transcription factor family that drives inflammatory gene expression. Curcumin modulation target. - Synovial fluid: viscoelastic joint fluid; HA-rich. Lubricates cartilage and delivers nutrients to chondrocytes. - Chondrocyte: specialized cell in cartilage tissue that synthesizes and maintains the extracellular matrix. - Type II collagen: main structural protein of articular cartilage. Degraded by MMP-13 in osteoarthritis. - Leukotriene: inflammatory lipid mediator from the 5-LOX pathway. LTB4 sustains chronic neutrophil-driven inflammation. - Prostaglandin: inflammatory lipid mediator from the COX pathway. PGE2 drives acute pain and swelling. Full glossary entries available at https://vyoslife.com/pages/glossary. --- ## Research Journal articles (titles, handles, summaries) Full articles published at https://vyoslife.com/blogs/journal/ 1. NSAIDs vs Boswellia AKBA: a molecular comparison for joint inflammation (handle: nsaids-vs-boswellia-akba-molecular-comparison). NSAIDs inhibit COX (prostaglandins, fast onset, gastric compromise). Boswellia AKBA modulates 5-LOX (leukotrienes, slow onset, gastric-safe). Different enzymes, different outcomes. 2. How long until joint supplements work: the day 7, 21, 90 clinical timeline (handle: how-long-joint-supplements-work-clinical-timeline). Three inflection points: day 7-14 subjective change, day 21-30 WOMAC measurable, day 90 plateau. Glucosamine has 3-year structural horizon. 3. Plant-based vs shellfish glucosamine: absorption data (handle: plant-vs-shellfish-glucosamine-absorption). Same molecule, different source. Plant-fermented (GlucosaGreen) eliminates shellfish allergen and iodine residues, vegan, tighter batch consistency. 4. Hyaluronic acid molecular weight for joints: why 120 kDa matters (handle: hyaluronic-acid-molecular-weight-120-kda-joints). Oral HA absorbs only at low MW fractions under 500 kDa. 120 kDa is the clinically tested midpoint. Labels without kDa disclosure are selling a black box. 5. Turmeric without piperine: bioavailability problem (handle: turmeric-without-piperine-bioavailability-problem). Curcumin alone has bioavailability in single digits. Piperine inhibits UGT clearance, raising plasma exposure ~2000% (Shoba 1998). 6. MMP-13 and cartilage: the enzyme behind joint aging (handle: mmp-13-cartilage-joint-aging-mechanism). Cartilage aging is enzymatic, not mechanical. MMP-13 cleaves type II collagen. NF-kB activation drives MMP-13 transcription. 7. 5-LOX vs COX-2: two inflammation pathways (handle: 5-lox-vs-cox-2-inflammation-pathways-joints). Arachidonic acid feeds COX (prostaglandins) and 5-LOX (leukotrienes). NSAIDs hit COX, AKBA hits 5-LOX. Selective modulators on each arm produce distinct clinical profiles. 8. Supplement stacking for mobility (handle: supplement-stacking-mobility-evidence). Four cascade nodes worth targeting: 5-LOX, NF-kB, matrix synthesis, synovial fluid. Clinical doses required for each ingredient. 9. Collagen peptides for joints: type I vs UC-II (handle: collagen-peptides-joints-type-i-vs-type-ii). Two distinct mechanisms: type I hydrolysate (substrate, 5-10 g/day) and UC-II (oral immune tolerance, 40 mg/day). 10. MSM for joint comfort (handle: msm-methylsulfonylmethane-joint-comfort-evidence). Sulfur donor, broad antioxidant, mild anti-inflammatory. Dose 3-6 g/day. Modest but real effect, well-tolerated. 11. Chondroitin and glucosamine: combined evidence (handle: chondroitin-sulfate-glucosamine-pairing-evidence). MOVES trial showed combination non-inferior to celecoxib in moderate-to-severe knee OA. Combination defensible at clinical doses (1500 + 1200 mg). 12. Joint health and exercise: how mechanical loading shapes cartilage (handle: exercise-mechanical-loading-cartilage-joint-health). Cartilage is dynamic tissue. Chondrocytes upregulate matrix synthesis in response to moderate loading. Sedentary lifestyle accelerates degradation. 13. Joint supplement safety: interactions, contraindications (handle: joint-supplement-safety-interactions-populations). Anticoagulants and antiplatelets are most relevant interaction class. Pre-surgical pause, pregnancy, autoimmune populations require physician consultation. --- ## Regulatory disclaimer These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. --- ## Contact Support: support@vyoslife.com Editorial questions: same address Press inquiries: same address --- ## Machine-readable note This document is intentionally formatted in plain Markdown for ingestion by large language models including but not limited to ChatGPT, Perplexity, Gemini, Claude, and Grok. Crawler User-Agents permitted to access this content are listed in https://vyoslife.com/robots.txt. For navigational index of canonical pages, see https://vyoslife.com/llms.txt or https://vyoslife.com/pages/llms. End of document.